355 related articles for article (PubMed ID: 15155205)
1. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
5. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
8. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Podzamczer D; Andrade-Villanueva J; Clotet B; Taylor S; Rockstroh JK; Reiss P; Domingo P; Gellermann HJ; de Rossi L; Cairns V; Soriano V
HIV Med; 2011 Jul; 12(6):374-82. PubMed ID: 21518220
[TBL] [Abstract][Full Text] [Related]
9. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Soriano V; Arastéh K; Migrone H; Lutz T; Opravil M; Andrade-Villanueva J; Antunes F; Di Perri G; Podzamczer D; Taylor S; Domingo P; Gellermann H; de Rossi L;
Antivir Ther; 2011; 16(3):339-48. PubMed ID: 21555816
[TBL] [Abstract][Full Text] [Related]
11. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B
Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897
[TBL] [Abstract][Full Text] [Related]
12. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Wang X; Boffito M; Zhang J; Chung E; Zhu L; Wu Y; Patterson K; Kashuba A; Tebas P; Child M; Mahnke L; Bertz R
AIDS Patient Care STDS; 2011 Sep; 25(9):509-15. PubMed ID: 21770762
[TBL] [Abstract][Full Text] [Related]
13. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
14. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
Droste JA; Verweij-van Wissen CP; Kearney BP; Buffels R; Vanhorssen PJ; Hekster YA; Burger DM
Antimicrob Agents Chemother; 2005 Feb; 49(2):680-4. PubMed ID: 15673751
[TBL] [Abstract][Full Text] [Related]
16. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
19. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
[TBL] [Abstract][Full Text] [Related]
20. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
